Switch to: References

Add citations

You must login to add citations.
  1. The First Smart Pill: Digital Revolution or Last Gasp?Anna K. Swartz & Phoebe Friesen - 2023 - Kennedy Institute of Ethics Journal 33 (3):277-319.
    ABSTRACT: Abilify MyCite was granted regulatory approval in 2017, becoming the world’s first “smart pill” that could digitally track whether patients had taken their medication. The new technology was introduced as one that had gained the support of patients and ethicists alike, and could contribute to solving the widespread and costly problem of patient nonadherence. Here, we offer an in-depth exploration of this narrative, through an examination of the origins and development of Abilify, the drug that would later become MyCite. (...)
    Direct download (3 more)  
     
    Export citation  
     
    Bookmark  
  • Considerations for applying bioethics norms to a biopharmaceutical industry setting.Wendell Fortson, Kathleen Novak Stern, Curtis Chang, Angela Rossetti, Ariella Kelman, Michael Turik, Donald G. Therasse, Tatjana Poplazarova & Luann E. Van Campen - 2021 - BMC Medical Ethics 22 (1).
    BackgroundThe biopharmaceutical industry operates at the intersection of life sciences, clinical research, clinical care, public health, and business, which presents distinct operational and ethical challenges. This setting merits focused bioethics consideration to complement legal compliance and business ethics efforts. However, bioethics as applied to a biopharmaceutical industry setting often is construed either too broadly or too narrowly with little examination of its proper scope.Main textAny institution with a scientific or healthcare mission should engage bioethics norms to navigate ethical issues that (...)
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark